Skyrizi vs Remicade for Ulcerative Colitis: Patient Guide

Skyrizi and Remicade represent two very different approaches to treating moderate-to-severe ulcerative colitis. Remicade has been the anti-TNF standard for UC since the mid-2000s. Skyrizi is a newer IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND trials. Patients commonly compare these drugs when starting a first biologic or considering alternatives after Remicade has lost effect. This guide walks through the skyrizi vs remicade ulcerative colitis decision.

Mechanism: IL-23 p19 vs Anti-TNF

Remicade (infliximab) is a chimeric monoclonal antibody that binds TNF-alpha, a cytokine that drives inflammation throughout the body and in the colon. Blocking TNF reduces inflammation systemically. Skyrizi (risankizumab) binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling. IL-23 is a central driver of Th17-mediated inflammation in UC. The risankizumab vs infliximab UC distinction matters because mechanism shapes both how fast each drug works and what its long-term safety profile looks like. Remicade's broader TNF blockade delivers rapid systemic anti-inflammatory effects. Skyrizi's selective IL-23 inhibition produces strong efficacy with a cleaner infection profile.

Efficacy in Ulcerative Colitis

Remicade's UC efficacy rests on the ACT-1 and ACT-2 trials, which established infliximab as one of the first effective UC biologics. Skyrizi's UC efficacy comes from INSPIRE (induction) and COMMAND (maintenance). INSPIRE showed clinical remission rates of 20.3% on Skyrizi versus 6.2% on placebo at week 12, with endoscopic improvement and symptomatic remission also significantly better. COMMAND showed sustained benefit through week 52. No head-to-head trial has directly compared Skyrizi with Remicade in UC. Indirect comparisons suggest Remicade has a slight edge on early induction remission, while Skyrizi offers strong maintenance outcomes and better performance in biologic-experienced patients.

Onset of Action

Remicade works fast in UC. Many patients report symptom improvement within the first two weeks of induction, with full response evident by week 8. Skyrizi's UC onset is slower, with meaningful response typically by week 12. For UC patients with severe, active disease who need rapid control (including those with acute severe UC), Remicade's faster action often matters clinically. For patients in less acute states or those weighing long-term administration and safety, Skyrizi's response trajectory is generally acceptable given the other advantages.

Safety and Infection Risk

Remicade carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Long-term IBD registry data consistently shows higher hospitalization rates for serious infection on infliximab compared with IL-23 pathway biologics. Skyrizi's UC safety data from INSPIRE and COMMAND has been favorable, consistent with its broader Crohn's and psoriasis experience. For skyrizi vs remicade UC effectiveness in patients with infection concerns, cancer history, or other risk factors for immunosuppression complications, Skyrizi's narrower mechanism often looks more favorable. Both drugs require TB and hepatitis B screening before starting.

Administration and Dosing

Remicade uses three IV induction doses at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks at 5 mg/kg for UC, with dose escalation to 10 mg/kg or interval shortening available if response wanes, per Janssen's Remicade information. Remicade requires lifelong infusions. Skyrizi for UC uses IV induction at weeks 0, 4, and 8 (1200 mg per infusion), followed by subcutaneous maintenance of 180 mg or 360 mg every 8 weeks. After induction, Skyrizi transitions patients to home-based SC injections, eliminating ongoing infusion center visits. For UC patients who want to minimize long-term infusion time, Skyrizi's SC maintenance is a meaningful practical advantage.

Switching From Remicade to Skyrizi

UC patients who lose response to Remicade often consider a mechanism switch rather than cycling to a second anti-TNF. INSPIRE included biologic-experienced patients and showed Skyrizi's efficacy in this population. Compared with cycling anti-TNFs (which typically delivers lower response rates than changing classes), a mechanism switch to IL-23 p19 blockade is supported by trial data. The skyrizi after remicade UC transition generally does not require a lengthy washout, though timing depends on residual Remicade levels, antidrug antibodies, and individual patient factors. Your GI will weigh these alongside disease severity when planning the switch.

Cost and Access

Remicade has extensive biosimilar competition. Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda) are widely available and often preferred on insurance formularies, which significantly lowers acquisition costs. Skyrizi has no biosimilar and is priced as a branded biologic. For UC patients where insurance strongly favors a low-cost infliximab biosimilar, Remicade (or its biosimilar) may be the most accessible option. For patients whose plans cover Skyrizi and who prioritize the IL-23 mechanism or SC maintenance convenience, manufacturer copay assistance programs can help bridge cost gaps for commercially insured patients.

Choosing With Your GI

For a UC patient deciding between Skyrizi and Remicade, Remicade tends to win on induction speed, dose escalation flexibility, and biosimilar cost savings. Skyrizi tends to win on long-term safety, SC maintenance convenience, and performance in anti-TNF experienced patients per INSPIRE data. Ask your GI how response will be measured after induction, what to do if symptoms persist, whether therapeutic drug monitoring will be used, and how your insurance handles infliximab biosimilars versus branded IL-23 biologics. A log of stool frequency, urgency, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.